← SynDRA
ANASTROZOLE
SynDRA canonical compound SYN0006069 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CYP19A1 |
|---|
| Mechanism of action | Aromatase inhibitor |
|---|
| Indication | breast cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- CYP19A1 INHIBITOR
- Cytochrome P450 19A1 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- UGT1A4
- ACHE
- HTR6
- MMP1
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LCK
- KCNH2
- HTR3A
- NPY1R
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HSD17B7
- HRH2
- HRH1
- HMGCR
- HDAC6
- MMP9
- NPY2R
- ADORA1
- NR3C1
- TBXAS1
- TACR2
- TACR1
- STS
- SLC6A4
- SLC6A3
- SLC6A2
- SIGMAR1
- SAMHD1
- PTPRC
- PTGS2
- PTGS1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP1A2
- CP2C9
- CP2CJ
- CP3A4
- CP3A7
Drug classes
- Aromatase Inhibitors
- Aromatase Inhibitor
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Enzyme Inhibitors
- Estrogen Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
ATC classes
- L02B · HORMONE ANTAGONISTS AND RELATED AGENTS
Cross-references
Synonyms
- ARIMIDEX
- Arimidex
- anastrazole
- anastrol
- arimidex
- Anastrozol
- Rvg-106400
- ICI-D1033
- NSC-719344
- NSC-759855
- ZD-1033
- ZD1033
- Nastrosa
- Anastrazole
- Anastrole
- Asiolex
- Astra brand of anastrozole
- AstraZeneca brand of anastrozole
- Zeneca brand of anastrozole
- Zeneca ZD 1033
- Arimidex (TN)
- Arimidex (Zeneca)
- Arimidex, Anastrozole
- Anastrozole [USAN:INN:BAN]
- Anastrozole (JAN/USAN/INN)
- ZD 1033
- NSC 719344
- NSC 759855
- 2Z07MYW1AZ
- CHEMBL1399
- CHEBI:2704
- NSC719344
- NCGC00164619-01
- SMR000466301
- CAS-120511-73-1
- HSDB 7462
- ICI-D 1033
Reported adverse events
- Arthritis
- Asthenia
- Fatigue
- Fracture
- Headache
- Osteoporosis
- Rash
- Somnolence
- Vomiting
- Cough
- Myalgia
- Bone pain
Look up ANASTROZOLE in the interactive SynDRA portal →